Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...

A fungal infection has been shown to trigger a fruit fly's own immune system to destroy brain cells, leading to signs of ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS candidate RFK Jr told senators the GLP-1s are ‘miracle drugs’ but shouldn’t ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...